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Discussion
• Does metformin at time of therapeutic treatment have more 
benefit then insulin in type 2 diabetics to control A1C?
• Is there a benefit of early intensive insulin therapy when added 
to metformin in type 2 diabetic patients to control their A1C? 
• What is the safety profile of metformin and insulin as 
monotherapy and dual-therapy for type 2 diabetics?
• What are the long-term benefits of starting intensive insulin 
early in the treatment of type 2 diabetes? 
• Remission rates after one year post therapy are found to be 
higher in the insulin group compared to the oral 
antihyperglycemic agents (p = 0.0012) (Cheng et al., 2008). 
• The ACCORD study showed increase mortality rate due to 
intensive insulin therapy. Intensive insulin therapy was shown 
to have some benefit by reducing the risk of retinopathy and 
microalbuminuria (Genuth and Ismail- Beigi, 2012).
• Three months after stopping intensive insulin therapy 66.2% of 
patients were in drug-free remission. The remission rate after 
six months 58.9%, twelve months 46.3%, and 42.1% after 24 
months. (Kramer, Retnakaran, and Zinman, 2013) 
• Short-term intensive insulin with metformin suggests remission 
rates of 51.1% for the continuous subcutaneous insulin infusion 
and 44.9% for the multiple daily injections (Weng et al., 2017).
• Insulin has less risk of hypoglycemia and weight gain when 
used with metformin. Insulin dosage is also decreased using 
combination therapy  (Halapy et al., 2012).
• Metformin used in dual therapy with insulin should be 
applied to a patient profile that meets current ADA 
guidelines.
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• The average time for insulin initiation is 11.5 years (Cohen et 
al., 2016). The importance of maintaining or achieving A1C 
goal is delaying the progression of microvascular, 
macrovascular, and other complications associated with 
T2DM.
• Despite evidence from landmark clinical trials and 
recommendations in published guidance, glycemic control is 
often poor for patients in clinical practice and insulin therapy 
can be delayed or not optimized (Cohen et al., 2016).
• CVD is a major reason for death among diabetics due to the 
extended period of abnormally high A1C.
• Current treatment guidelines do not have an option to treat 
patients with intensive insulin therapy. 
Metformin has been proven beneficial for the first-line 
treatment of type 2 diabetic mellitus (T2DM) due to its efficacy 
and low adverse effect profile. Current US guidelines do not 
address the use of early intensive insulin use in T2DM. 
Treatment plans are slowly adjusted over the months until the 
A1C goal is met. Insulin is initiated several years after the time 
of T2DM diagnosis and utilized as second-line therapy. Dual 
therapy of insulin and metformin have shown regression of 
T2DM in certain patient populations. However, the linear 
relationship between diabetes and cardiovascular disease does 
not show greater improvement with dual aggressive therapy. 
The ACCORD study found intensive insulin use has led to an 
increase in mortality in diabetic patients. The purpose of this 
literature review is to gather data using clinical studies and 
peer-reviewed articles that can determine if metformin and 
insulin should be used intensively to lower A1C aggressively 
compared to using standard therapy of metformin to decrease 
the long-term effects of abnormal A1C levels.
Keywords: insulin, metformin, dual therapy, regression, 
mortality, A1C, intensive insulin therapy, guidelines 
• Reversing β-cell dysfunction can lead to remission after one 
year in 44% of type 2 diabetic patients that have been treated 
with intensive insulin therapy (Ferrannini et al., 2018). 
• 7 in 10 people 
with diabetes 
over the age of 
65 will die of 
some type of 
heart disease 
(CDC, 2017). 
• For every one 
percent 
increase in 
A1C, a 
patients risk 
of CVD event 
increases by 
16%. 
• The Center for Disease Control and Prevention (CDC) 
estimates 9.4% of the U.S. population has T2DM, another 33% 
of adults have prediabetes.
• Initiation of drug therapy should consider the clinical 
characteristics of the patient profile, efficacy of the drug, side 
effects, and cost. 
• The ideal patient for receiving intensive therapy are lower 
fasting plasma glucose and a higher BMI at baseline (Kramer, 
2013)
• Insulin has been used in short course studies such as Opsteen 
et al. (2010) and Ferrannini et al. (2018) to induce diabetic 
remission
• One of the downfalls of metformin is the progressive loss of 
efficacy as expressed in Ferrannini et al. (2018)
• Providers are more apprehensive of starting insulin than the 
patients are (Halapy et al. 2012).
• Insulin is often withheld from treatment regimens because of 
its perceived negative impact on the patient’s quality of life 
(QOL) (Weng et al. 2017). 
• In the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial, intensive glycemic control significantly 
reduced the risk and/or progression of retinopathy, 
nephropathy, and neuropathy (ADA, 2009)
• The Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) study had a premature stop due to the 22% 
increase in the mortality rate of intensively treated T2DM 
patients
• The United Kingdom Prospective Diabetes Study  (UKPDS) 
data found no increase in mortality from intensive insulin 
therapy
• Patients that could benefit from dual metformin and 
intensive insulin therapy are younger adults that have 
new onset of T2DM and lower baseline A1C
• The patients that should avoid or follow closely  when 
intensive insulin therapy are older adults (> 55 years 
old), have had CVD or other risk factors for CVD, and 
have had T2DM for several years
• Start insulin therapy shortly after the diagnosis of 
T2DM when starting dual therapy with metformin.
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